UTHR - United Therapeutics Corporation
NASDAQ
->
Healthcare
->
Biotechnology
Silver Spring,
United States
Type: Equity
UTHR price evolution
UTHR
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1355.7 | $1251.5 | $1207.7 | |
| Short term investments | $1615.8 | $1456.3 | $1786.4 | |
| Net receivables | $341.8 | $290.7 | $307.3 | $278.9 |
| Inventory | $146.7 | $136.5 | $120.2 | $111.8 |
| Total current assets | $4000.4 | $3619.5 | $3248.7 | $3551 |
| Long term investments | $1330.4 | $1491.9 | $1909.8 | |
| Property, plant & equipment | $1156.7 | $1094.6 | $1074 | $1045.4 |
| Goodwill & intangible assets | $115.2 | $115.4 | $114.2 | |
| Total noncurrent assets | $3103.7 | $3246.5 | $3616 | |
| Total investments | $2946.2 | $2948.2 | $3696.2 | |
| Total assets | $7123.1 | $6723.2 | $6495.2 | $7167 |
| Current liabilities | ||||
| Accounts payable | $363.9 | $325.3 | $305.1 | $298 |
| Deferred revenue | ||||
| Short long term debt | $400 | $400 | $400 | |
| Total current liabilities | $873.4 | $832.3 | $860.6 | $804.4 |
| Long term debt | $100 | $200 | $300 | |
| Total noncurrent liabilities | $193.7 | $296.5 | $377.8 | |
| Total debt | $500 | $600 | $700 | |
| Total liabilities | $1022.2 | $1026 | $1157.1 | $1182.2 |
| Shareholders' equity | ||||
| Retained earnings | $6920.9 | $6611.8 | $6333.7 | $6027.1 |
| Other shareholder equity | $7.4 | -$14.9 | -$15.6 | -$12.8 |
| Total shareholder equity | $5697.2 | $5338.1 | $5984.8 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1207.7 | $961.2 | $894.8 | $738.7 |
| Short term investments | $1786.4 | $1877.5 | $1035.9 | $1096.3 |
| Net receivables | $278.9 | $220.4 | $198.7 | $157.4 |
| Inventory | $111.8 | $102 | $93.8 | $86.5 |
| Total current assets | $3551 | $3380.3 | $2323.6 | $2167.2 |
| Long term investments | $1909.8 | $1316.2 | $1649.9 | $1149.6 |
| Property, plant & equipment | $1045.4 | $861.5 | $780.9 | $731.6 |
| Goodwill & intangible assets | $114.2 | $44.5 | $44.6 | $158.1 |
| Total noncurrent assets | $3616 | $2664.2 | $2845.5 | $2447.8 |
| Total investments | $3696.2 | $3193.7 | $2685.8 | $2245.9 |
| Total assets | $7167 | $6044.5 | $5169.1 | $4615 |
| Current liabilities | ||||
| Accounts payable | $298 | $4.1 | $174.6 | $187 |
| Deferred revenue | ||||
| Short long term debt | $400 | |||
| Total current liabilities | $804.4 | $343.2 | $305.4 | $323.3 |
| Long term debt | $300 | $800 | $800 | $800 |
| Total noncurrent liabilities | $377.8 | $904.6 | $904.8 | $896.5 |
| Total debt | $700 | $800 | $800 | $800 |
| Total liabilities | $1182.2 | $1247.8 | $1210.2 | $1219.8 |
| Shareholders' equity | ||||
| Retained earnings | $6027.1 | $5042.3 | $4315 | $3839.2 |
| Other shareholder equity | -$12.8 | $0.9 | -$23 | -$14.2 |
| Total shareholder equity | $5984.8 | $4796.7 | $3958.9 | $3395.2 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $748.9 | $714.9 | $677.7 | $614.7 |
| Cost of revenue | $77.8 | $72.9 | $71 | |
| Gross Profit | $665.8 | $637.1 | $604.8 | $543.7 |
| Operating activities | ||||
| Research & development | $139.6 | $104.1 | $151.4 | |
| Selling, general & administrative | $177.6 | $144.4 | $132.2 | |
| Total operating expenses | $257.6 | $317.2 | $248.5 | $283.6 |
| Operating income | $319.9 | $356.3 | $260.1 | |
| Income from continuing operations | ||||
| EBIT | $366.9 | $411.9 | $310.5 | |
| Income tax expense | $79.5 | $77.2 | $92 | $78.3 |
| Interest expense | $36.6 | $11.6 | $13.3 | $15.1 |
| Net income | ||||
| Net income | $309.1 | $278.1 | $306.6 | $217.1 |
| Income (for common shares) | $278.1 | $306.6 | $217.1 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2327.5 | $1936.3 | $1685.5 | $1483.3 |
| Cost of revenue | $257.5 | $151.6 | $122.5 | $108.1 |
| Gross Profit | $2070 | $1784.7 | $1563 | $1375.2 |
| Operating activities | ||||
| Research & development | $408 | $322.9 | $540.1 | $357.7 |
| Selling, general & administrative | $477.1 | $482.1 | $467 | $423.9 |
| Total operating expenses | $885.1 | $805 | $1007.1 | $781.6 |
| Operating income | $1184.9 | $979.7 | $555.9 | $593.6 |
| Income from continuing operations | ||||
| EBIT | $1333.6 | $983 | $612.5 | $662.4 |
| Income tax expense | $289.5 | $223.3 | $118.1 | $124.1 |
| Interest expense | $59.3 | $32.4 | $18.6 | $23.5 |
| Net income | ||||
| Net income | $984.8 | $727.3 | $475.8 | $514.8 |
| Income (for common shares) | $984.8 | $727.3 | $475.8 | $514.8 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $278.1 | $306.6 | $217.1 | |
| Operating activities | ||||
| Depreciation | $18.7 | $15 | $13.7 | |
| Business acquisitions & disposals | -$89.2 | |||
| Stock-based compensation | $49.7 | $25.6 | $16.6 | |
| Total cash flows from operations | $232.2 | $376.5 | $150.7 | |
| Investing activities | ||||
| Capital expenditures | -$45.1 | -$38.2 | -$78.7 | |
| Investments | -$34.9 | $773.5 | $210 | |
| Total cash flows from investing | $540.4 | -$80 | $735.3 | $42.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $52.1 | -$957.8 | $7.3 | |
| Net borrowings | -$100 | -$102.7 | -$100 | |
| Total cash flows from financing | -$1180.1 | -$48 | -$1068 | -$92.8 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $346.2 | $104.2 | $43.8 | $100 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $984.8 | $727.3 | $475.8 | $514.8 |
| Operating activities | ||||
| Depreciation | $53.2 | $51.3 | $49.9 | $49.9 |
| Business acquisitions & disposals | -$89.2 | $8.6 | ||
| Stock-based compensation | $39.1 | $106.8 | $138.5 | $163.8 |
| Total cash flows from operations | $978 | $802.5 | $598.2 | $755.7 |
| Investing activities | ||||
| Capital expenditures | -$230.4 | -$138.8 | -$120.8 | -$56.9 |
| Investments | -$400 | -$681.3 | -$366.1 | -$681.6 |
| Total cash flows from investing | -$719.6 | -$811.5 | -$486.9 | -$738.5 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $98 | $88.4 | $55.6 | $38.5 |
| Net borrowings | -$102.7 | -$7.5 | -$51.7 | |
| Total cash flows from financing | -$11.9 | $75.4 | $44.8 | -$16.9 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $246.5 | $66.4 | $156.1 | $0.3 |
News
Fundamentals
| Market cap | $18.68B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 44.62M |
| Revenue | $2.76B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $1.11B |
| Revenue Q/Q | 22.89% |
| Revenue Y/Y | 25.04% |
| P/E ratio | 16.81 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 6.78 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $24.90 |
|---|---|
| ROA | 16.15% |
| ROE | N/A |
| Debt/Equity | 0.20 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.58 |
| Quick ratio | 4.41 |